Radiopharm Theranostics Limited

RADX · NASDAQ
Analyze with AI
6/30/2025
6/30/2024
6/30/2023
6/30/2022
Operating Activities
Net Income$0-$47,949-$34,611-$30,339
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$0$0$0$0
Other Non-Cash-$36,645$24,973$11,409$20,423
Operating Cash Flow-$36,645-$22,976-$23,202-$9,916
Investing Activities
PP&E Inv.$0$0-$45-$3
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$1,771-$320-$1,485-$28,367
Investing Cash Flow$1,771-$320-$1,531-$28,370
Financing Activities
Debt Repay.-$1,900$2,202$0-$59
Stock Issued$53,978$29,646$10,073$70,000
Stock Repurch.$0-$1,534-$855-$4,831
Dividends Paid$0$0$0$0
Other Fin. Act.-$6,646-$117$0$0
Financing Cash Flow$45,432$30,197$9,218$65,110
Forex Effect-$15-$25$235$127
Net Chg. in Cash$10,542$6,876-$15,280$26,952
Supplemental Information
Beg. Cash$18,575$11,699$26,979$27
End Cash$29,117$18,575$11,699$26,979
Free Cash Flow-$36,645-$22,976-$24,732-$38,254
Radiopharm Theranostics Limited (RADX) Financial Statements & Key Stats | AlphaPilot